Literature DB >> 21242963

Identification of a progenitor cell of origin capable of generating diverse meningioma histological subtypes.

M Kalamarides1, A O Stemmer-Rachamimov, M Niwa-Kawakita, F Chareyre, E Taranchon, Z-Y Han, C Martinelli, E A Lusis, B Hegedus, D H Gutmann, M Giovannini.   

Abstract

Meningiomas are among the most common primary central nervous system tumours in adults. Studies focused on the molecular basis for meningioma development are hampered by a lack of information with regard to the cell of origin for these brain tumours. Herein, we identify a prostaglandin D synthase-positive meningeal precursor as the cell of origin for murine meningioma, and show that neurofibromatosis type 2 (Nf2) inactivation in prostaglandin D2 synthase (PGDS) (+) primordial meningeal cells, before the formation of the three meningeal layers, accounts for the heterogeneity of meningioma histological subtypes. Using a unique PGDSCre strain, we define a critical embryonic and early postnatal developmental window in which biallelic Nf2 inactivation in PGDS (+) progenitor cells results in meningioma formation. Moreover, we identify differentially expressed markers that characterize the two major histological meningioma subtypes both in human and mouse tumours. Collectively, these findings establish the cell of origin for these common brain tumours as well as a susceptible developmental period in which signature genetic mutations culminate in meningioma formation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21242963     DOI: 10.1038/onc.2010.609

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  51 in total

1.  Radiation risk of central nervous system tumors in the Life Span Study of atomic bomb survivors, 1958-2009.

Authors:  Alina V Brenner; Hiromi Sugiyama; Dale L Preston; Ritsu Sakata; Benjamin French; Atsuko Sadakane; Elizabeth K Cahoon; Mai Utada; Kiyohiko Mabuchi; Kotaro Ozasa
Journal:  Eur J Epidemiol       Date:  2020-01-25       Impact factor: 8.082

Review 2.  Advances in meningioma genetics: novel therapeutic opportunities.

Authors:  Matthias Preusser; Priscilla K Brastianos; Christian Mawrin
Journal:  Nat Rev Neurol       Date:  2018-01-05       Impact factor: 42.937

3.  The expression of the MSC-marker CD73 and of NF2/Merlin are correlated in meningiomas.

Authors:  Elmar Kirches; Tabea Steffen; Natalie Waldt; Eva Hebert; Doreen Pachow; Annette Wilisch-Neumann; Gerburg Keilhoff; Thomas Schneider; Werner E K Braunsdorf; Jan-Peter Warnke; Christian Mawrin
Journal:  J Neurooncol       Date:  2018-02-21       Impact factor: 4.130

Review 4.  Neurofibromatosis-related tumors: emerging biology and therapies.

Authors:  Matthias A Karajannis; Rosalie E Ferner
Journal:  Curr Opin Pediatr       Date:  2015-02       Impact factor: 2.856

Review 5.  Optimizing biologically targeted clinical trials for neurofibromatosis.

Authors:  David H Gutmann; Jaishri O Blakeley; Bruce R Korf; Roger J Packer
Journal:  Expert Opin Investig Drugs       Date:  2013-02-21       Impact factor: 6.206

Review 6.  Meningiomas from a developmental perspective: exploring the crossroads between meningeal embryology and tumorigenesis.

Authors:  Julien Boetto; Matthieu Peyre; Michel Kalamarides
Journal:  Acta Neurochir (Wien)       Date:  2020-11-20       Impact factor: 2.216

Review 7.  Hand in glove: brain and skull in development and dysmorphogenesis.

Authors:  Joan T Richtsmeier; Kevin Flaherty
Journal:  Acta Neuropathol       Date:  2013-03-23       Impact factor: 17.088

8.  Histone deacetylase inhibitor AR-42 differentially affects cell-cycle transit in meningeal and meningioma cells, potently inhibiting NF2-deficient meningioma growth.

Authors:  Sarah S Burns; Elena M Akhmametyeva; Janet L Oblinger; Matthew L Bush; Jie Huang; Volker Senner; Ching-Shih Chen; Abraham Jacob; D Bradley Welling; Long-Sheng Chang
Journal:  Cancer Res       Date:  2012-11-14       Impact factor: 12.701

9.  In vivo metabolism of tryptophan in meningiomas is mediated by indoleamine 2,3-dioxygenase 1.

Authors:  Ian M Zitron; David O Kamson; Sam Kiousis; Csaba Juhász; Sandeep Mittal
Journal:  Cancer Biol Ther       Date:  2013-01-28       Impact factor: 4.742

Review 10.  Medical management of meningiomas.

Authors:  Wendy J Sherman; Jeff J Raizer
Journal:  CNS Oncol       Date:  2013-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.